[go: up one dir, main page]

DK3394045T3 - Co-krystal, fremstillingsfremgangsmåde deraf og medikament som indeholder co-krystal. - Google Patents

Co-krystal, fremstillingsfremgangsmåde deraf og medikament som indeholder co-krystal. Download PDF

Info

Publication number
DK3394045T3
DK3394045T3 DK16831645.3T DK16831645T DK3394045T3 DK 3394045 T3 DK3394045 T3 DK 3394045T3 DK 16831645 T DK16831645 T DK 16831645T DK 3394045 T3 DK3394045 T3 DK 3394045T3
Authority
DK
Denmark
Prior art keywords
crystal
manufacturing procedure
medicine containing
medicine
procedure
Prior art date
Application number
DK16831645.3T
Other languages
English (en)
Inventor
Koya Kimoto
Mitsuo Yamamoto
Masato Kitayama
Yasuhiro Sawai
Miyuki Hohokabe
Kentaro Iwata
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of DK3394045T3 publication Critical patent/DK3394045T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/08Malonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50Mandelic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10Salicylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK16831645.3T 2015-12-24 2016-12-22 Co-krystal, fremstillingsfremgangsmåde deraf og medikament som indeholder co-krystal. DK3394045T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015252658 2015-12-24
PCT/JP2016/089224 WO2017111179A1 (en) 2015-12-24 2016-12-22 Cocrystal, production method thereof, and medicament containing cocrystal

Publications (1)

Publication Number Publication Date
DK3394045T3 true DK3394045T3 (da) 2021-08-16

Family

ID=57910088

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16831645.3T DK3394045T3 (da) 2015-12-24 2016-12-22 Co-krystal, fremstillingsfremgangsmåde deraf og medikament som indeholder co-krystal.

Country Status (25)

Country Link
US (1) US10836745B2 (da)
EP (1) EP3394045B1 (da)
JP (1) JP6876704B2 (da)
KR (1) KR102687603B1 (da)
CN (1) CN108473467B (da)
AR (1) AR107132A1 (da)
AU (1) AU2016375899B2 (da)
CA (1) CA3009610C (da)
CL (1) CL2018001725A1 (da)
CO (1) CO2018006473A2 (da)
DK (1) DK3394045T3 (da)
EA (1) EA039213B1 (da)
EC (1) ECSP18055921A (da)
ES (1) ES2877089T3 (da)
HK (1) HK1256362A1 (da)
IL (1) IL260195A (da)
MX (1) MX380656B (da)
PH (1) PH12018501356A1 (da)
PL (1) PL3394045T3 (da)
SG (1) SG11201805331QA (da)
TN (1) TN2018000221A1 (da)
TW (1) TWI722080B (da)
UY (1) UY37046A (da)
WO (1) WO2017111179A1 (da)
ZA (1) ZA201804393B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020006587B1 (pt) * 2017-10-06 2024-01-09 Cargill, Incorporated Solução aquosa de glicosídeo de esteviol, composição de bebida, adoçante, e, método para solubilizar uma composição total de glicosídeo de esteviol
WO2019071220A1 (en) 2017-10-06 2019-04-11 Cargill, Incorporated SENSORY MODIFYING COMPOUNDS
JP2022527518A (ja) 2019-04-06 2022-06-02 カーギル インコーポレイテッド 感覚改質剤
CN110818692B (zh) * 2019-11-08 2023-03-24 中国海洋大学 一种替加氟与丁香酸的共晶及其制备方法
TWI845802B (zh) * 2020-04-21 2024-06-21 健亞生物科技股份有限公司 硫酸羥氯喹之晶體
CN117383998A (zh) * 2023-09-28 2024-01-12 天津理工大学 一种共晶的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
BR9812866A (pt) 1997-10-07 2000-08-08 Schering Corp Polimorfo antifúngico cristalino
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2008105195A1 (ja) 2007-02-28 2008-09-04 Nsk Ltd. チルト式ステアリング装置
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
JP2013512886A (ja) 2009-12-03 2013-04-18 アストラゼネカ アクチボラグ 血小板の凝集阻害剤トリアゾロ[4,5−d]ピリミジン共結晶
EP2731612A4 (en) 2011-07-13 2015-04-08 Pharmacyclics Inc BRUTON TYROSINE KINASE HEMMER
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
JP6876704B2 (ja) 2021-05-26
KR20180095933A (ko) 2018-08-28
PL3394045T3 (pl) 2021-09-27
EP3394045B1 (en) 2021-05-19
ES2877089T3 (es) 2021-11-16
AR107132A1 (es) 2018-03-21
JP2019504025A (ja) 2019-02-14
MX2018007721A (es) 2018-08-15
ECSP18055921A (es) 2018-10-31
AU2016375899B2 (en) 2021-05-13
TWI722080B (zh) 2021-03-21
UY37046A (es) 2017-07-31
US20170183326A1 (en) 2017-06-29
EA039213B1 (ru) 2021-12-17
CN108473467B (zh) 2021-08-13
IL260195A (en) 2018-07-31
SG11201805331QA (en) 2018-07-30
CA3009610A1 (en) 2017-06-29
CN108473467A (zh) 2018-08-31
CL2018001725A1 (es) 2018-10-19
WO2017111179A1 (en) 2017-06-29
TN2018000221A1 (en) 2019-10-04
PH12018501356A1 (en) 2019-02-18
TW201730181A (zh) 2017-09-01
BR112018012915A2 (pt) 2018-12-11
KR102687603B1 (ko) 2024-07-24
HK1256362A1 (zh) 2019-09-20
CA3009610C (en) 2024-02-13
EP3394045A1 (en) 2018-10-31
AU2016375899A1 (en) 2018-07-19
ZA201804393B (en) 2019-09-25
CO2018006473A2 (es) 2018-07-10
US10836745B2 (en) 2020-11-17
EA201891467A1 (ru) 2018-12-28
MX380656B (es) 2025-03-12

Similar Documents

Publication Publication Date Title
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
DK3168283T3 (da) Hydrokrakning-katalysator, fremstillingsfremgangsmåde og anvendelse deraf
DK3347472T3 (da) Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf.
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
DK3234124T3 (da) Proteasevarianter og polynukleotider, som koder for dem.
DK2986304T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
DK3234093T3 (da) Proteasevarianter og polynukleotider, som koder for dem
DK3234123T3 (da) Proteasevarianter og polynukleotider, som koder for dem
HUE054551T2 (hu) Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
DK3424924T3 (da) Ureaforbindelse, fremgangsmåde til fremstilling deraf og medicinsk anvendelse deraf
LT3310345T (lt) Burnoje disperguojama tabletė, turinti estetrolio
EP3713931C0 (en) 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDE
DK3294449T3 (da) Pulverformigt titaniumoxid, fremgangsmåde til fremstilling deraf og anvendelse deraf
EP3729459A4 (en) RECOMMENDATION ON DIABETES DRUGS
DK3394045T3 (da) Co-krystal, fremstillingsfremgangsmåde deraf og medikament som indeholder co-krystal.
DK3464260T3 (da) Forbindelser, der indeholder ureamotiver, og derivater deraf som antibakterielle lægemidler
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
ES1150114Y (es) Abarcón.
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler
DK3181556T3 (da) Mikromolekyleforbindelse, fremgangsmåde til syntese og anvendelse deraf
IT201600069848A1 (it) Friggitrice.